drugset
drugset / Trial / NCT04388761

Feasibility and Safety of Allogeneic Adipose Mesenchymal Stem Cells (aMSCs) Delivery Into Kidney Allografts Procured From Deceased Donors With High Kidney Donor Profile Index (KDPI)

NCT04388761 ↗

Phase 1 Withdrawn Tambi Jarmi
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this research is to test an investigational drug called Adipose Mesenchymal Stem Cells (aMSCs) for the treatment of ischemia re-perfusion injury (IRI) in patients that have had a kidney transplant.

Timeline

Start
2020-09
Primary completion
2024-02
Completion
2024-02

Outcome

Outcome not reported

Stopped (Enrollment): “Challenges in recruiting participants.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Allogeneic Adipose-derived Mesenchymal Stem Cells Cell therapy — Other

Indications

ischemic disease